QGEN Stock Might Rise Following Partnership With Genomics England

Zacks01-08 19:54

QIAGEN N.V. QGEN recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2501727167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 19:54","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501727167","market":"us","top_or_hot":-1,"title":"QGEN Stock Might Rise Following Partnership With Genomics England","media":"Zacks","content":"<div>\n<p>QIAGEN N.V. QGEN recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study...</p>\n\n<a href=\"https://finance.yahoo.com/news/qgen-stock-might-rise-following-115400926.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QGEN Stock Might Rise Following Partnership With Genomics England</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQGEN Stock Might Rise Following Partnership With Genomics England\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/qgen-stock-might-rise-following-115400926.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>QIAGEN N.V. QGEN recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study...</p>\n\n<a href=\"https://finance.yahoo.com/news/qgen-stock-might-rise-following-115400926.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/qgen-stock-might-rise-following-115400926.html","article_id":"2501727167","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501727167","pubTimestamp":1736337240,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"QIAGEN N.V. QGEN recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study for 100,000 newborns to screen over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.The latest partnership aims to broaden the utilization of QIAGEN’s Genomics portfolio.Over the past few quarters, QIAGEN’s Genomics portfolio has witnessed robust revenue growth. Recently, the company has been involved in several value-added collaborations to bolster its presence in the Genomics space. In 2024, QIAGEN partnered with Element Biosciences to offer NGS workflow on the latter’s AVITI System. Accordingly, we expect the latest partnership with Genomics England to bolster investor confidence and create an upward momentum in QGEN's share price in the upcoming days.A key differentiator of the QIAGEN Clinical Knowledge Base is its combination of the unmatched accu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","RMD.AU":"Resmed DRC","VCYT":"Veracyte Inc","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","OMCL":"Omnicell","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","BK4139":"生物科技","BK4159":"经销商","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4167":"医疗保健技术","BK4082":"医疗保健设备","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","BK4121":"生命科学工具和服务","CAGR":"California Grapes International, Inc.","LU1923622614.USD":"Natixis Thematics Meta R/A USD","BK4588":"碎股","RMD":"瑞思迈","BK4504":"桥水持仓"},"translate_title":"与Genomics England合作后QGEN股价可能会上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1,"RMD":1,"QGEN":1,"OMCL":1,"CAGR":1,"RMD.AU":0.9},"content_text":"QIAGEN N.V. QGEN recently partnered with Genomics England to support the delivery of the Generation Study. QIAGEN’s Clinical Knowledge Base will power a first-of-its-kind whole-genome sequencing study for 100,000 newborns to screen over 200 selected conditions, enabling earlier diagnosis and treatment of rare conditions.\nThe latest partnership aims to broaden the utilization of QIAGEN’s Genomics portfolio.\nLikely Trend of QGEN Stock Following the News\nFollowing the announcement, shares of the company remained unchanged at $44.94 in aftermarket trading yesterday.\nOver the past few quarters, QIAGEN’s Genomics portfolio has witnessed robust revenue growth. Recently, the company has been involved in several value-added collaborations to bolster its presence in the Genomics space. In 2024, QIAGEN partnered with Element Biosciences to offer NGS workflow on the latter’s AVITI System. Accordingly, we expect the latest partnership with Genomics England to bolster investor confidence and create an upward momentum in QGEN's share price in the upcoming days. \nQIAGEN currently has a market capitalization of $9.95 billion. The company delivered an average earnings surprise of 3.52% for the trailing four quarters.\nDetails on QIAGEN’s Partnership With Genomics England \nThe QIAGEN Clinical Knowledge Base offers comprehensive genomic content built on expert manual curation. Newborn sequencing benefits greatly from pre-curated knowledge, which is readily comparable to each newborn’s DNA. \nVariant interpretation is important for the Generation Study. QIAGEN curators provided comprehensive evidence for every variant seen across the 200 conditions included in the study to support Genomics England’s ability to safely return results to participants. \nAbout the Generation Study \nLaunched in 2024, the Generation Study will sequence and analyze the genomes of 100,000 newborns for a set of actionable genetic conditions that may affect their health in their early years. The study identifies conditions such as Metachromatic leukodystrophy (MLD) in babies. Further, it benefits hundreds of babies from earlier diagnosis and treatment that could help slow the progression of rare conditions and even extend their lives.\nAbout QIAGEN Clinical Knowledge Base \nThe QIAGEN Clinical Knowledge Base contains biological content from more than 40 databases, curated for clinical relevance. It has been used by researchers, clinicians, and pharmaceutical companies for more than 25 years and has been cited in more than 35,000 scientific publications. \nA key differentiator of the QIAGEN Clinical Knowledge Base is its combination of the unmatched accuracy and consistency of QIAGEN’s proprietary expert curation with the superior efficiency of machine extraction to efficiently identify, extract and align evidence. To date, the QIAGEN Clinical Knowledge Base has been used to analyze and interpret more than 4 million NGS patient test cases globally. \nImage Source: Zacks Investment Research\nIndustry Prospects Favor QIAGEN\nPer a report by Grand View Research, the global whole genome sequencing market size is expected to witness a compound annual growth rate (CAGR) of 22.17% from 2025 to 2030. The market is experiencing significant growth, driven by a confluence of technological advancements, decreasing costs and a growing demand for personalized medicine. \nRecent Developments by QIAGEN\nLast month, QIAGEN launched Ingenuity Pathway Analysis (“IPA”) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data. Leveraging AI technology, IPA Interpret helps researchers understand which genes are involved in a disease, a biological process or a response to a drug or environmental condition. IPA Interpret is an integrated component of QIAGEN IPA. \nThe same month, QIAGEN reached a milestone with more than 1000 EZ2 Connect automated sample preparation instrument placements. \nQGEN’s Price Performance\nIn the past six-month, QGEN’s shares have risen 12.2% compared with the industry’s 7.4% growth.\nQGEN’s Zacks Rank and Key Picks\nThe company currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Veracyte VCYT, ResMed RMD and Omnicell OMCL.\nVeracyte, carrying a Zacks Rank of #1 (Strong Buy) at present, has an estimated earnings growth rate of 65.8% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.\nVCYT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 520.58%. Veracyte’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.\nResMed, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 21.1% for 2025. \nRMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.41%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year. \nOmnicell, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 72.7% for fourth-quarter 2024. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 121.74%.\nOMCL’s shares have risen 26.4% against the industry’s 15.7% decline in the past year. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nOmnicell, Inc. (OMCL) : Free Stock Analysis Report\nResMed Inc. (RMD) : Free Stock Analysis Report\nQIAGEN N.V. (QGEN) : Free Stock Analysis Report\nVeracyte, Inc. (VCYT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2501727167"}